Summary of Key Points Core Viewpoint - On May 23, 2025, Zhaoyan New Drug (603127) closed at 17.3 yuan, marking a 2.73% increase with a turnover rate of 6.57% and a trading volume of 414,000 shares, amounting to a transaction value of 718 million yuan [1]. Trading Information - On May 23, 2025, the net outflow of main funds for Zhaoyan New Drug was 9.2293 million yuan, while the net inflow from speculative funds was 4.6736 million yuan, and the net inflow from retail investors was 4.5556 million yuan [2]. Company Announcements - Zhaoyan New Drug announced on May 22, 2025, that its member companies subscribed to four structured deposit products from Jiangsu Bank, with a total investment of 440 million yuan. The company confirmed that all other financial products previously subscribed to Jiangsu Bank have been fully redeemed, and these investments are not expected to adversely affect the financial status of the company [1][2]. Structured Deposit Plans - Zhaoyan (Suzhou) New Drug signed a principal-protected floating return structured deposit plan with Jiangsu Bank for 150 million yuan, with an expected annual return rate of 0.1%-2.45%, starting on November 22, 2024, and maturing on May 22, 2025 [3]. - Zhaoyan Management Technology signed a principal-protected floating return structured deposit plan with Jiangsu Bank for 60 million yuan, with an expected annual return rate of 1.60%-2.50%, starting on December 27, 2024, and maturing on December 27, 2025 [3]. - Zhaoyan Management Technology also signed a principal-protected floating return structured deposit plan with Jiangsu Bank for 200 million yuan, with an expected annual return rate of 1.00%-2.56%, starting on February 26, 2025, and maturing on August 26, 2025 [3]. - Additionally, Zhaoyan (Suzhou) New Drug signed a principal-protected floating return structured deposit plan for 30 million yuan, with an expected annual return rate of 1.50% or 2.45%, starting on May 23, 2025, and maturing on November 23, 2025 [3].

Core Viewpoint - JOINN Laboratories (China) Co., Ltd. has announced the further subscription of structured deposit products from Jiangsu Bank, totaling RMB 440 million, which is expected to yield reasonable interest without adversely affecting the company's financial situation [1][5]. Summary by Sections Subscription of Financial Products - The company has subscribed to four structured deposit products from Jiangsu Bank, with the total investment amounting to RMB 440 million [1][4]. - The first product has an investment of RMB 150 million with an expected annual return rate of 0.1%–2.45%, maturing on May 22, 2025 [4]. - The second product involves an investment of RMB 60 million with an expected annual return rate of 1.60%–2.50%, maturing on December 27, 2025 [4]. - The third product has an investment of RMB 200 million with an expected annual return rate of 1.00%–2.56%, maturing on August 26, 2025 [4]. - The fourth product involves an investment of RMB 30 million with an expected annual return rate of 1.50% or 2.45%, maturing on November 23, 2025 [4]. Current Status - As of the announcement date, the company confirmed that all previously subscribed financial products have been redeemed according to their terms, except for the structured deposit products from Jiangsu Bank [5]. - The company believes that the structured deposit products will yield reasonable interest and will not negatively impact its financial condition [5]. Reasoning and Benefits for Subscription - The company aims to utilize excess cash in its capital account without affecting operational liquidity by subscribing to these structured deposit products, which offer higher interest rates compared to regular bank deposits [5]. - The structured deposit products are considered low-risk and are expected to provide better returns than typical commercial bank deposits in China [5].